AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8026027
Drug: lovastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin 80 mg/d
Trial: 21190985
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg twice daily lorcaserin
Trial: 15730351
Drug: Tiagabine 20
RxNorm normalized name: tiaGABine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 20 mg
Trial: 1618109
Drug: Fluorouracil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (400 mg/m2 daily for 5 days)
Trial: 1618109
Drug: Fluorouracil combined
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil combined with folic acid (100 mg/m2 before each dose of fluorouracil)
Trial: 6324332
Drug: Ranitidine tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine tablets, 150 mg twice daily
Trial: 31187447
Drug: Bergamot oil
RxNorm normalized name: Bergamot Oil
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bergamot oil nanospanlastics combined with PUVB therapy
Trial: 26547718
Drug: Revised version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Revised version of the FDA Drug Safety Communication (DSC)
Trial: 26547718
Drug: Standard version
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard version of the FDA Drug Safety Communication (DSC)
Trial: 26547718
Drug: Both versions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both versions of the FDA Drug Safety Communication (DSC)
Trial: 24740826
Drug: Epirubicin/cyclophosphamide (EC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) with bevacizumab (B, 15 mg/kg q3w)
Trial: 24740826
Drug: Epirubicin/cyclophosphamide (EC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) without bevacizumab
Trial: 20404353
Drug: High-dose vigabatrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vigabatrin (100-148 mg/kg/d)
Trial: 20404353
Drug: Low-dose vigabatrin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vigabatrin (18-36 mg/kg/d)
Trial: 28933338
Drug: 24 µg
RxNorm normalized name: penicillin G 24 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 µg of lubiprostone 30 minutes prior to the study
Trial: 28933338
Drug: 24 µg
RxNorm normalized name: penicillin G 24 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 µg of lubiprostone plus 10 mg of domperidone 30 minutes prior to the study
Trial: 11061253
Drug: Riluzole 100
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole 100 mg/day
Trial: 11061253
Drug: Riluzole 200
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole 200 mg/day
Trial: 9359740
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated Japanese encephalitis vaccine (SA14-14-2)
Trial: 26617202
Drug: S-1 (40-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day break)
Trial: 26617202
Drug: Taxane (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane (docetaxel 60-75 mg/m2 at intervals of 3-4 weeks; paclitaxel 80-100 mg/m2 weekly for 3 of 4 weeks; or paclitaxel 175 mg/m2 at intervals of 3-4 weeks)
Trial: 22898443
Drug: Symptom-triggered treatment
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-triggered treatment protocol
Trial: 19664302
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 2 g/d
Trial: 19664302
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 4 g/d
Trial: 19664302
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 6 g/d
Trial: 19664302
Drug: Sunola oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunola oil (control; 6 g/d)
Trial: 18678802
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (n = 33)
Trial: 15358441
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles
Trial: 15358441
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles + 800 mg of vaginal progesterone
Trial: 15358441
Drug: Intravenous pregnanolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pregnanolone (3alpha‐hydroxy‐5beta‐pregnan‐20‐one)
Trial: 28072459
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing integrated with cognitive behavioral therapy (MI-CBT)
Trial: 24366622
Drug: Plasma homocysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma homocysteine increase of 5.0 μmol/l
Trial: 23167181
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus antifungal therapy during operation and postoperation
Trial: 19419318
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prevalent vertebral fracture and FRAX with FN BMD
Trial: 9412659
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (n = 5)
Trial: 9412659
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (n = 6)
Trial: 8505824
Drug: Perioperative total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative total parenteral nutrition (TPN)
Trial: 3325316
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fentiazac twice daily for 3 weeks
Trial: 3325316
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac sodium twice daily for 3 weeks
Trial: 23378398
Drug: Glutamine/amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine/amino acid solution
Trial: 12544740
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg fresh frozen plasma
Trial: 9792579
Drug: Budesonide forte
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide forte (1,200 mg/d) for 6 weeks
Trial: 7707113
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy and chemotherapy (vindesine 3 mg/m2 on days 1, 8, 29, and 36; cisplatin 100 mg/m2 on days 1 and 29; mitomycin 8 mg/m2 on days 1 and 29; radiotherapy for 3 weeks with 2 Gy given 13 times)
Trial: 2540136
Drug: Trimethoprim-polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-polymyxin B sulphate ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Trial: 2540136
Drug: Chloramphenicol ophthalmic
RxNorm normalized name: chloramphenicol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Trial: 30810254
Drug: Dapagliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5 mg/d for 24 weeks)
Trial: 27703067
Drug: 8% Papain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% Papain gel
Trial: 27703067
Drug: Carbopol gel
RxNorm normalized name: Carbopol 981
DrugBank: Carbomer (DB15649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbopol gel (control)
Trial: 24314186
Drug: Propranolol (2‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2‐3 mg/kg/d)
Trial: 24314186
Drug: Prednisolone (1‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1‐4 mg/kg/d)
Trial: 21677329
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 1,200 mg
Trial: 19555621
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide administered as a 2-minute bolus (BG)
Trial: 19555621
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide administered as a slow infusion for 15 minutes (IG)
Trial: 15304173
Drug: Complete distal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete distal aortic occlusion (</=60 min, with heparin and protamine reversal)
Trial: 31994476
Drug: Cannabidiol (CBD),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol (CBD), 600 mg, orally administered
Trial: 31301615
Drug: bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion XL 150 mg, 300 mg, 300 mg (once-daily)
Trial: 31301615
Drug: escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram 10 mg, 10 mg, 10-20 mg (once-daily)
Trial: 29037805
Drug: Olaparib capsules
RxNorm normalized name: Olaparib Capsules
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib capsules (400 mg PO b.i.d.)
Trial: 23736824
Drug: Single‐injection ipsilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐injection ipsilateral interscalene brachial plexus block
Trial: 21442813
Drug: Hour-prescription of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hour-prescription of points (acupoints of Spleen Meridian selected from 10:04 a.m. to 12:04 a.m.)
Trial: 17870419
Drug: Chiropractic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic manual therapy only
Trial: 17870419
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy followed by exercise
Trial: 15318306
Drug: Radionuclide methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radionuclide methods (99mTc‐diethyl‐IDA injection, 360 MBq)
Trial: 11403533
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of proton pump inhibitors twice daily with H2-receptor antagonist at bedtime
Trial: 8041415
Drug: Protracted infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protracted infusion of fluorouracil during pelvic irradiation
Trial: 8041415
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of systemic fluorouracil alone
Trial: 3052971
Drug: Graduated progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graduated progressive training (aerobic conditioning and strength exercises) performed twice weekly for 8 weeks
Trial: 29630516
Drug: Basic body
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic body awareness therapy (BBAT)
Trial: 26099553
Drug: Low-dose Huo-Luo-Xiao-Ling
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (2400 mg/day) for 6 weeks
Trial: 26099553
Drug: High-dose Huo-Luo-Xiao-Ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (4000 mg/day for week 1-2, and 5600 mg/day for week 3-8) for 8 weeks
Trial: 15062145
Drug: HDR (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDR (high-dose rate) intracavitary brachytherapy
Trial: 15062145
Drug: MDR (medium-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDR (medium-dose rate) intracavitary brachytherapy
Trial: 10920215
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral calcitriol (0.5 microg/day) combined with nasal salmon calcitonin (200 U/day) for the first 3 months (group A)
Trial: 10920215
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous pamidronate (0.5 mg/kg body weight) every third month (group B)
Trial: 10920215
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (calcitriol with calcitonin and pamidronate)
Trial: 3877287
Drug: Control (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (all other drugs)
Trial: 30532155
Drug: Narrative Community‐Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Community‐Based Group Therapy
Trial: 15571828
Drug: abciximab (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) during the organization phase for pPCI (Group 1, n=28)
Trial: 15571828
Drug: abciximab (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) immediately before pPCI (Group 2, n=27)
Trial: 27353271
Drug: Velpatasvir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velpatasvir (150 mg)
Trial: 25090617
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25.0 mg/day)
Trial: 20368235
Drug: intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intensive medical therapy alone
Trial: 20368235
Drug: insulin sensitization
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: insulin sensitization therapy
Trial: 20368235
Drug: insulin provision
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: insulin provision therapy
Trial: 10719944
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 800 microg (three consecutive doses)
Trial: 10719944
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 15 microg/kg
Trial: 30408272
Drug: Lip trill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lip trill therapy
Trial: 30408272
Drug: Straw phonation
RxNorm normalized name: oat straw extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straw phonation therapy
Trial: 30408272
Drug: Water-resistance therapy
RxNorm normalized name: copper naphthenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-resistance therapy (WRT)
Trial: 25813205
Drug: Palbociclib 100
RxNorm normalized name: palbociclib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (IV) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 and days 15 and 18
Trial: 23045618
Drug: Multiple-dose DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose DAS181
Trial: 18577791
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy for 12 weeks
Trial: 16172952
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus rituximab (MCP+R)
Trial: 16172952
Drug: Chemotherapy (MCP)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (MCP)
Trial: 16172952
Drug: Mantle cell
RxNorm normalized name: garden lady's mantle extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mantle cell lymphoma treatment
Trial: 10432137
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of PGE2 (Prepidil) administered intracervically at 39 weeks' gestation, repeated weekly for up to three doses.
Trial: 10432137
Drug: Expectant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant treatment (control group).
Trial: 2111220
Drug: Glucose-electrolyte solution
RxNorm normalized name: glucose Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-electrolyte solution labeled with stable isotope H2O18
Trial: 20678233
Drug: Telephone-delivered behavioural
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered behavioural weight loss intervention focusing on physical activity, diet, and behavioural therapy (18 months duration, with a 6-month intensive phase and a 12-month maintenance phase).
Trial: 17656445
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion (3 kcal/min for 60 min)
Trial: 16783811
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean dose 637 mg/day, mean treatment duration 80 days)
Trial: 16783811
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dose 16 mg/day, mean treatment duration 78 days)
Trial: 10783609
Drug: Individual outcome-oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual outcome-oriented cardiologic rehabilitation treatment
Trial: 8627110
Drug: Mixed antileprosy
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed antileprosy vaccine containing killed Mycobacterium leprae of human origin plus M. bovis BCG
Trial: 8627110
Drug: Multidrug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug therapy (MDT) only
Trial: 3918196
Drug: 15% glucose‐3.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% glucose‐3.3% Intralipid‐5% amino acid solution (group G‐F)
Trial: 3918196
Drug: 25% glucose‐5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% glucose‐5% amino acid solution (group G)
Trial: 3918196
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (group G and group G‐F)
Trial: 31706658
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula oxygen (HFNC) at a flow of 60 L/min
Trial: 31706658
Drug: Conventional reserve-bag
RxNorm normalized name: obecabtagene autoleucel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional reserve-bag oxygen therapy (NBO2) at a flow of 15 L/min
Trial: 31706658
Drug: Conventional reserve-bag
RxNorm normalized name: obecabtagene autoleucel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional reserve-bag oxygen therapy (NBO2)
Trial: 10972687
Drug: Prednisolone 60
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 60 mg/m2 daily for six weeks, followed by 40 mg/m2 on alternate days for six weeks
Trial: 10972687
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg/m2 daily for six weeks
Trial: 1473873
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride in polyethylene glycol (MHP) suppository
Trial: 1473873
Drug: Morphine alkaloid
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alkaloid in Novata BBC (MAN) suppository
Trial: 6202753
Drug: Ketoconazole, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole, 400 mg once daily (K)
Trial: 6202753
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B tablets and lozenges (A)
Trial: 29687877
Drug: Adenosine combined
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine combined with micro-pump intravenous infusion of tirofiban
Trial: 22008899
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (topiramate plus nortriptyline)
Trial: 22008899
Drug: Monotherapy (placebo)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (placebo)
Trial: 17337492
Drug: Ramipril 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5/10 mg